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CONCLUSIONS: Schizophrenia patients consume signif-
icant health care resources. Medications used to treat
schizophrenia did not differ in terms of duration of ther-
apy or impact on total health care costs.
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Hospitals, health care systems, and policy makers are
striving to seek ways to provide cost-effective care for pa-
tients with major depressive disorder.
OBJECTIVES: The first objective is to investigate the dif-
ferences between the newer antidepressants regarding
treatment completion, average daily dose, dosage titration,
switching, and augmentation behavior. The second objec-
tive is to compare direct health service expenditures related
to the treatment of depression. The inquiry is guided by the
following question: Is there a significant difference be-
tween antidepressants in regard to overall health care ser-
vice expenditures for the treatment of depression?
METHODS: Retrospective archival data from computer-
ized claims records of a large managed care organization
were analyzed. Treatment completion was defined as re-
ceiving at least 180 days of therapy at a minimum thera-
peutic dose as defined by the AHCPR guidelines for de-
tection, diagnosis, and treatment of depression. Patients
were included in the analysis if (1) they had an ICD-9 di-
agnosis code for depression or if (2) they received an anti-
depressant prescription. Patients were excluded if (1) they
were less than 18 years of age, (2) they had a diagnosis
indicating schizophrenia or bipolar depression, (3) there
were not at least 6 months of follow up data available, or
(4) they were ineligible for coverage by the plan.
RESULTS: Patients initiated on fluoxetine were more
likely to complete therapy than those on paroxetine, ser-
traline, nefazodone, or venlafaxine (n = 65,792; p <
.01). These differences narrowed over time. Results re-
garding overall health care utilization related to each an-
tidepressant will be presented.
CONCLUSIONS: Based on this sample of patients, it ap-
pears that patients initiated on fluoxetine are more likely
to complete therapy when compared to the other anti-
depressants.
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While sedative-hypnotic agents may be equally effective
in promoting sleep, some may lead to greater impairment
in psychomotor functioning and an increased risk of mo-
tor vehicle accidents (MYAs).
OBJECTIVE: To create a general model of the impact of
alternative sedative-hypnotic agents on the expected num-
bers and associated costs of MYAs.
METHODS: A decision-analytic model was developed to
compare the effects of alternative sedative-hypnotics over
one month in a hypothetical cohort of 100,000 adult
drivers who were not being treated with these agents.
Since insomnia increases the risk of driving drowsy, pos-
sibly leading to additional MYAs, a scenario of no treat-
ment was included for comparison purposes. Outcomes
included the expected numbers of drowsy drivers and
MYAs, and the costs (societal) associated with MYAs.
Model parameters were estimated using published sur-
veys, randomized clinical trials of driving performance,
and epidemiologic studies relating driving impairment to
the risk of MYAs.
RESULTS: If sedative-hypnotics were not used, there
would be 24,300 drowsy drivers (per 100,000 per
month) and 441 MYAs. Monthly accident costs would be
$36 per person. Treatment with a sedative-hypnotic asso-
ciated with limited impairment (e.g., nitrazepam 5 mg
daily) would reduce the number of drowsy drivers to
17,550 but only slightly reduce MYAs (by 2) and
monthly costs (by less than $1 per patient). A medication
that might severely impair driving (e.g., flurazepam 30
mg daily) would not further reduce the number of drowsy
drivers but more than triple MYAs (to 1,488) and
monthly costs (to $122 per person).
CONCLUSIONS: Some sedative-hypnotic agents may
markedly increase the costs of MYAs. Their acquisition
prices alone therefore may provide a poor indication of
overall economic impact.
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Long periods of antipsychotic pharmacotherapy are often
necessary because many of the psychotic conditions indi-
cated for antipsychotics are chronic in nature. Atypical
antipsychotic agents, with a broader response profile and
fewer side effects, may increase the likelihood of achiev-
ing longer periods of pharmacotherapy relative to typical
antipsychotic agents.
OBJECTIVE: This study compares the duration of con-
tinuous therapy between atypical and typical antipsy-
chotics in the naturalistic care setting.
METHODS: Three years of medical claims data from a
large U.S. prescription database were analyzed for 56,682
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patients with at least one antipsychotic prescription be-
tween 5/1 and 7/31/1995. A patient's first antipsychotic
prescription (the index prescription) during this interval
was used to classify each patient into an atypical or a typ-
ical antipsychotic cohort. Patients were further classified
into "new" or "continuing" cohorts based on whether or
not the patients had received any antipsychotic prescrip-
tions during the 12-month period preceding their index
prescriptions. Duration of continuous therapy, defined as
the total number of antipsychotic days supplied to a pa-
tient prior to a period of 31 or more days with no anti-
psychotic medications, was tracked over a two-year pe-
riod after the index prescription.
RESULTS: Duration of continuous therapy was 201 :!::
266 (rnean z. SD) days for all patients. For atypical anti-
psychotics, the duration of continuous therapy was 301
:!:: 299 days for new users and 347 :!:: 308 days for con-
tinuing users. In contrast, the duration of continuous
therapy for typical antipsychotics was 136 :!:: 229 days
for new users and 257 :!:: 278 days for continuing users.
CONCLUSION: Patients on atypical antipsychotics have
a longer duration of continuous therapy.
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Adherence to antipsychotic therapy is associated with
greater likelihood of positive outcomes for schizophrenia
treatment. Atypical antipsychotic agents, with broader
response profiles and greater tolerability, may increase
the probability of compliance with drug therapy relative
to typical antipsychotic agents.
OBJECTIVE: This study compares month-to-month ad-
herence to pharmacotherapy between atypical and typical
antipsychotics in the naturalistic care setting.
METHODS: Claims from a large U.S. prescription data-
base were analyzed for 56,682 patients who received at
least one antipsychotic prescription between 5/1 and 7/31/
1995. A patient's first antipsychotic prescription (the in-
dex prescription) during this interval was used to classify
the patient from an intent-to-treat perspective as an atyp-
ical or typical antipsychotic user. Month-to-month ad-
herence to pharmacotherapy for 32,066 patients who did
not receive an antipsychotic prescription during the 12-
month period preceding their index prescriptions were
tracked over a two-year period following their index pre-
scriptions. Month-to-month adherence on drug therapy
was measured as possessing at least 15 days of the same
antipsychotic within a 3D-day period.
RESULTS: Almost all (97%) atypical antipsychotics re-
cipients successfully completed at least one month of
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compliance on pharmacotherapy, compared to only half
(53%) of recipients on typical antipsychotics. At the 6th
month, 54% of atypical and 26% of typical antipsychotic
recipients were compliant. These percentages declined to
45% and 22% at the 12th month, 40% and 19% at the
18th month, and 11 % and 5 % at the 24th month for
atypical versus typical antipsychotic recipients, respec-
tively.
CONCLUSION: Measured over a maximum of 24
months, patients on atypical anti psychotics were more
likely to adhere on a month-to-month basis with antipsy-
chotic therapy.
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OBJECTIVE: The purpose of this study was to assess the
impact of commonly applied research selection criteria on
the proportion of patients initiated on fluoxetine, parox-
etine, or sertraline who received only the initial agent, at
the same dose, for 90 or more continuous days.
METHODS: This retrospective utilization analysis of a
large u.s. prescription claims database grouped patients
initiating on fluoxetine, paroxetine, or sertraline into
samples with (typical design, n = 17,825) and without
(relaxed design, n = 291,758) commonly applied re-
search selection criteria. Patients selected were 18 or
older and eligible during the respective review periods.
Patients in the typical design had no prior period use of
antidepressants and no use of other psychotropics. Pa-
tients who maintained 90 or more continuous days of
therapy exclusively on their initial study drug and who
did not experience dose escalation were assigned a stable
utilization pattern. All others were assigned a non-stable
utilization pattern.
RESULTS: The typical design had significantly (p :s
0.001) fewer patients with a stable utilization pattern
(29% typical, 32% relaxed). The percentage of patients
achieving a stable utilization pattern with fluoxetine was
at least five percentage points greater, a significant (p :S
0.001) difference, than the percentage for either paroxet-
ine or sertraline. The stable pattern was significantly
more likely for sertraline than paroxetine patients in the
relaxed design (29.7%, 29.1 %, p = 0.017) but not in the
typical design (26.5%,26.6%, p = 0.920).
CONCLUSIONS: A stable utilization pattern is more
likely with fluoxetine than with paroxetine or sertraline
initiated patients. The stable pattern's relative relation-
ship is robust across designs for fluoxetine but not for
paroxetine and sertraline.
